Allogene Therapeutics Financials
This page shows Allogene Therapeutics (ALLO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Allogene Therapeutics's revenue declined 100% year-over-year, from $22K to $0. This contraction results in a growth score of 0/100.
Allogene Therapeutics carries a low D/E ratio of 0.42, meaning only $0.42 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.93, Allogene Therapeutics holds $7.93 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Allogene Therapeutics generates a -65.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -61.0% the prior year.
Allogene Therapeutics passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Allogene Therapeutics generates $0.78 in operating cash flow (-$149.2M OCF vs -$190.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Allogene Therapeutics earns $-194.7 in operating income for every $1 of interest expense (-$209.3M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Allogene Therapeutics generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Allogene Therapeutics's EBITDA was -$197.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.1% from the prior year.
Allogene Therapeutics reported -$190.9M in net income in fiscal year 2025. This represents an increase of 25.9% from the prior year.
Allogene Therapeutics earned $-0.87 per diluted share (EPS) in fiscal year 2025. This represents an increase of 34.1% from the prior year.
Cash & Balance Sheet
Allogene Therapeutics generated -$149.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 25.6% from the prior year.
Allogene Therapeutics held $51.7M in cash against $0 in long-term debt as of fiscal year 2025.
Allogene Therapeutics paid $0.00 per share in dividends in fiscal year 2025.
Allogene Therapeutics had 229M shares outstanding in fiscal year 2025. This represents an increase of 8.1% from the prior year.
Margins & Returns
Allogene Therapeutics's ROE was -65.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.2 percentage points from the prior year.
Capital Allocation
Allogene Therapeutics invested $150.2M in research and development in fiscal year 2025. This represents a decrease of 21.9% from the prior year.
Allogene Therapeutics invested $386K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 44.4% from the prior year.
ALLO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0-100.0% | $22K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $31.2M-22.4% | $40.2M-20.0% | $50.2M | N/A | $44.7M-11.2% | $50.4M-3.6% | $52.3M |
| SG&A Expenses | N/A | $13.7M-3.8% | $14.3M-4.7% | $15.0M | N/A | $16.3M+1.5% | $16.1M-6.8% | $17.3M |
| Operating Income | N/A | -$44.9M+21.0% | -$56.8M+12.8% | -$65.2M | N/A | -$71.8M-0.5% | -$71.4M-2.8% | -$69.5M |
| Interest Expense | N/A | $344K+28.4% | $268K+78.7% | $150K | N/A | $100K | $0 | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$41.4M+18.7% | -$50.9M+14.7% | -$59.7M | N/A | -$66.3M+0.1% | -$66.4M-2.1% | -$65.0M |
| EPS (Diluted) | N/A | $-0.19+17.4% | $-0.23+17.9% | $-0.28 | N/A | $-0.32+8.6% | $-0.35+7.9% | $-0.38 |
ALLO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $415.9M-5.4% | $439.8M-6.5% | $470.6M-7.4% | $508.0M-7.4% | $548.7M-6.9% | $589.1M-8.9% | $646.9M+10.3% | $586.4M |
| Current Assets | $257.7M-1.1% | $260.7M-7.8% | $282.7M-3.1% | $291.6M-3.9% | $303.4M-0.3% | $304.4M-33.4% | $457.1M+15.6% | $395.4M |
| Cash & Equivalents | $51.7M+36.7% | $37.8M-27.7% | $52.3M+23.3% | $42.5M-43.6% | $75.2M+46.8% | $51.2M-70.0% | $170.7M+234.4% | $51.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $123.4M-0.9% | $124.4M-1.3% | $126.0M+2.8% | $122.6M-3.1% | $126.5M+0.9% | $125.4M-4.9% | $131.8M+5.5% | $125.0M |
| Current Liabilities | $32.5M+2.1% | $31.8M+0.5% | $31.7M+5.5% | $30.0M-15.5% | $35.5M+9.1% | $32.6M-12.7% | $37.3M+20.8% | $30.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $292.5M-7.2% | $315.3M-8.5% | $344.6M-10.6% | $385.4M-8.7% | $422.2M-9.0% | $463.7M-10.0% | $515.0M+11.6% | $461.4M |
| Retained Earnings | -$2.0B-2.0% | -$2.0B-2.1% | -$1.9B-2.7% | -$1.9B-3.3% | -$1.8B-3.4% | -$1.8B-3.9% | -$1.7B-4.1% | -$1.6B |
ALLO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.6M+7.0% | -$29.7M+23.9% | -$39.0M+26.3% | -$52.9M-44.2% | -$36.7M+16.8% | -$44.1M+30.6% | -$63.6M-13.8% | -$55.9M |
| Capital Expenditures | $0-100.0% | $243K+452.3% | $44K-55.6% | $99K-61.5% | $257K-40.1% | $429K | $0-100.0% | $8K |
| Free Cash Flow | -$27.6M+7.8% | -$29.9M+23.4% | -$39.1M+26.3% | -$53.0M-43.5% | -$37.0M+17.0% | -$44.5M+29.9% | -$63.6M-13.7% | -$55.9M |
| Investing Cash Flow | $33.6M+181.6% | $11.9M-72.8% | $43.8M+609.8% | $6.2M-88.8% | $54.9M+172.3% | -$76.0M-201.8% | $74.6M+237.1% | $22.1M |
| Financing Cash Flow | $7.9M+142.9% | $3.2M-36.2% | $5.1M-63.7% | $14.0M+143.6% | $5.7M+745.8% | $679K-99.4% | $108.6M+6482.0% | $1.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ALLO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -315927.3% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -295454.6% |
| Return on Equity | N/A | -13.1%+1.6pp | -14.8%+0.7pp | -15.5% | N/A | -14.3%-1.4pp | -12.9%+1.2pp | -14.1% |
| Return on Assets | N/A | -9.4%+1.4pp | -10.8%+0.9pp | -11.8% | N/A | -11.3%-1.0pp | -10.3%+0.8pp | -11.1% |
| Current Ratio | 7.93-0.3 | 8.19-0.7 | 8.92-0.8 | 9.71+1.2 | 8.54-0.8 | 9.35-2.9 | 12.25-0.5 | 12.80 |
| Debt-to-Equity | 0.42+0.0 | 0.39+0.0 | 0.37+0.0 | 0.32+0.0 | 0.30+0.0 | 0.27+0.0 | 0.26-0.0 | 0.27 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -254122.7% |
Similar Companies
Frequently Asked Questions
What is Allogene Therapeutics's annual revenue?
Allogene Therapeutics (ALLO) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Allogene Therapeutics's revenue growing?
Allogene Therapeutics (ALLO) revenue declined by 100% year-over-year, from $22K to $0 in fiscal year 2025.
Is Allogene Therapeutics profitable?
No, Allogene Therapeutics (ALLO) reported a net income of -$190.9M in fiscal year 2025.
What is Allogene Therapeutics's EBITDA?
Allogene Therapeutics (ALLO) had EBITDA of -$197.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Allogene Therapeutics's return on equity (ROE)?
Allogene Therapeutics (ALLO) has a return on equity of -65.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Allogene Therapeutics's free cash flow?
Allogene Therapeutics (ALLO) generated -$149.6M in free cash flow during fiscal year 2025. This represents a 25.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Allogene Therapeutics's operating cash flow?
Allogene Therapeutics (ALLO) generated -$149.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Allogene Therapeutics's total assets?
Allogene Therapeutics (ALLO) had $415.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Allogene Therapeutics's capital expenditures?
Allogene Therapeutics (ALLO) invested $386K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Allogene Therapeutics spend on research and development?
Allogene Therapeutics (ALLO) invested $150.2M in research and development during fiscal year 2025.
What is Allogene Therapeutics's current ratio?
Allogene Therapeutics (ALLO) had a current ratio of 7.93 as of fiscal year 2025, which is generally considered healthy.
What is Allogene Therapeutics's debt-to-equity ratio?
Allogene Therapeutics (ALLO) had a debt-to-equity ratio of 0.42 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Allogene Therapeutics's return on assets (ROA)?
Allogene Therapeutics (ALLO) had a return on assets of -45.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Allogene Therapeutics's cash runway?
Based on fiscal year 2025 data, Allogene Therapeutics (ALLO) had $51.7M in cash against an annual operating cash burn of $149.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Allogene Therapeutics's Piotroski F-Score?
Allogene Therapeutics (ALLO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Allogene Therapeutics's earnings high quality?
Allogene Therapeutics (ALLO) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Allogene Therapeutics cover its interest payments?
Allogene Therapeutics (ALLO) has an interest coverage ratio of -194.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Allogene Therapeutics?
Allogene Therapeutics (ALLO) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.